Keros Therapeutics (NASDAQ:KROS) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a strong sell rating to a sell rating in a research report report published on Saturday.

KROS has been the topic of several other research reports. Weiss Ratings downgraded shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Leerink Partners cut their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a report on Tuesday. Finally, Zacks Research lowered Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 29th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Keros Therapeutics has an average rating of “Hold” and an average target price of $20.50.

Keros Therapeutics Stock Up 4.7%

NASDAQ:KROS opened at $11.15 on Friday. The business’s 50-day simple moving average is $10.62 and its two-hundred day simple moving average is $12.39. The stock has a market cap of $221.07 million, a PE ratio of -3.01 and a beta of 0.99. Keros Therapeutics has a 52 week low of $9.69 and a 52 week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Sell-side analysts anticipate that Keros Therapeutics will post -5.12 earnings per share for the current fiscal year.

Insider Transactions at Keros Therapeutics

In related news, Director Julius Knowles sold 2,625 shares of Keros Therapeutics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director owned 10,958 shares in the company, valued at approximately $117,579.34. This trade represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the sale, the director directly owned 9,767 shares in the company, valued at $104,702.24. The trade was a 21.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,425 shares of company stock worth $89,994 in the last three months. Insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Keros Therapeutics in the 2nd quarter worth approximately $29,898,000. Deutsche Bank AG purchased a new position in Keros Therapeutics during the second quarter worth $501,000. Bank of New York Mellon Corp purchased a new position in Keros Therapeutics during the second quarter worth $1,106,000. ADAR1 Capital Management LLC increased its position in Keros Therapeutics by 416.2% during the first quarter. ADAR1 Capital Management LLC now owns 97,318 shares of the company’s stock valued at $1,074,000 after acquiring an additional 78,467 shares during the last quarter. Finally, Empowered Funds LLC increased its position in Keros Therapeutics by 142.2% during the first quarter. Empowered Funds LLC now owns 145,517 shares of the company’s stock valued at $1,607,000 after acquiring an additional 85,439 shares during the last quarter. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.